Literature DB >> 11841783

Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.

Robert Mauritz1, Godefridus J Peters, David G Priest, Yehuda G Assaraf, Stavit Drori, Ietje Kathmann, Paul Noordhuis, Marlene A Bunni, Andre Rosowsky, Jan H Schornagel, Herbert M Pinedo, Gerrit Jansen.   

Abstract

We determined the mechanisms of resistance of human CCRF-CEM leukemia cells to methotrexate (MTX) vs. those to six novel antifolates: the polyglutamatable thymidylate synthase (TS) inhibitors ZD1694, multitargeted antifolate, pemetrexed, ALIMTA (MTA) and GW1843U89, the non-polyglutamatable inhibitors of TS, ZD9331, and dihydrofolate reductase, PT523, as well as DDATHF, a polyglutamatable glycinamide ribonucleotide transformylase inhibitor. CEM cells were made resistant to these drugs by clinically relevant intermittent 24 hr exposures to 5-10 microM of MTX, ZD1694, GW1843U89, MTA and DDATHF, by intermittent 72 hr exposures to 5 microM of ZD9331 and by continuous exposure to stepwise increasing concentrations of ZD9331, GW1843U89 and PT523. Development of resistance required only 3 cycles of intermittent drug exposure to ZD1694 and MTA, but 5 cycles for MTX, DDATHF and GW1843U89 and 8 cycles for ZD9331. The predominant mechanism of resistance to ZD1694, MTA, MTX and DDATHF was impaired polyglutamylation due to approximately 10-fold decreased folylpolyglutamate synthetase activity. Resistance to intermittent exposures to GW1843U89 and ZD9331 was associated with a 2-fold decreased transport via the reduced folate carrier (RFC). The CEM cell lines resistant to intermittent exposures to MTX, ZD1694, MTA, DDATHF, GW1843U89 and ZD9331 displayed a depletion (up to 4-fold) of total intracellular reduced folate pools. Resistance to continuous exposure to ZD9331 was caused by a 14-fold increase in TS activity. CEM/GW70, selected by continuous exposure to GW1843U89 was 50-fold resistant to GW1843U89, whereas continuous exposure to PT523 generated CEM/PT523 cells that were highly resistant (1550-fold) to PT523. Both CEM/GW70 and CEM/PT523 displayed cross-resistance to several antifolates that depend on the RFC for cellular uptake, including MTX (95- and 530-fold). CEM/GW70 cells were characterized by a 12-fold decreased transport of [3H]MTX. Interestingly, however, CEM/GW70 cells displayed an enhanced transport of folic acid, consistent with the expression of a structurally altered RFC resulting in a 2.6-fold increase of intracellular folate pools. CEM/PT523 cells displayed a markedly impaired (100-fold) transport of [3H]MTX along with 12-fold decreased total folate pools. In conclusion, multifunctional mechanisms of resistance in CEM cells have a differential impact on cellular folate homeostasis: decreased polyglutamylation and transport defects lead to folate depletion, whereas a structurally altered RFC protein can provoke expanded intracellular folate pools.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11841783     DOI: 10.1016/s0006-2952(01)00824-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

Review 1.  The antifolates.

Authors:  Michele Visentin; Rongbao Zhao; I David Goldman
Journal:  Hematol Oncol Clin North Am       Date:  2012-06       Impact factor: 3.722

2.  Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs.

Authors:  J van der Heijden; M C de Jong; B A C Dijkmans; W F Lems; R Oerlemans; I Kathmann; G L Scheffer; R J Scheper; Y G Assaraf; G Jansen
Journal:  Ann Rheum Dis       Date:  2004-02       Impact factor: 19.103

3.  Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate.

Authors:  K-J Sohn; F Smirnakis; D N Moskovitz; P Novakovic; Z Yates; M Lucock; R Croxford; Y-I Kim
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

4.  Single agent and combination studies of pralatrexate and molecular correlates of sensitivity.

Authors:  M Serova; I Bieche; M-P Sablin; G J Pronk; M Vidaud; E Cvitkovic; S Faivre; E Raymond
Journal:  Br J Cancer       Date:  2010-12-21       Impact factor: 7.640

5.  Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.

Authors:  Benshang Li; Samuel W Brady; Xiaotu Ma; Shuhong Shen; Yingchi Zhang; Yongjin Li; Karol Szlachta; Li Dong; Yu Liu; Fan Yang; Ningling Wang; Diane A Flasch; Matthew A Myers; Heather L Mulder; Lixia Ding; Yanling Liu; Liqing Tian; Kohei Hagiwara; Ke Xu; Xin Zhou; Edgar Sioson; Tianyi Wang; Liu Yang; Jie Zhao; Hui Zhang; Ying Shao; Hongye Sun; Lele Sun; Jiaoyang Cai; Hui-Ying Sun; Ting-Nien Lin; Lijuan Du; Hui Li; Michael Rusch; Michael N Edmonson; John Easton; Xiaofan Zhu; Jingliao Zhang; Cheng Cheng; Benjamin J Raphael; Jingyan Tang; James R Downing; Ludmil B Alexandrov; Bin-Bing S Zhou; Ching-Hon Pui; Jun J Yang; Jinghui Zhang
Journal:  Blood       Date:  2020-01-02       Impact factor: 25.476

6.  Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia.

Authors:  Anna Wojtuszkiewicz; Godefridus J Peters; Nicole L van Woerden; Boas Dubbelman; Gabriele Escherich; Kjeld Schmiegelow; Edwin Sonneveld; Rob Pieters; Peter M van de Ven; Gerrit Jansen; Yehuda G Assaraf; Gertjan J L Kaspers; Jacqueline Cloos
Journal:  J Hematol Oncol       Date:  2015-05-29       Impact factor: 17.388

7.  Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers.

Authors:  E Izbicka; A Diaz; R Streeper; M Wick; D Campos; R Steffen; M Saunders
Journal:  Cancer Chemother Pharmacol       Date:  2009-02-17       Impact factor: 3.333

8.  γ-Glutamyl hydrolase modulation and folate influence chemosensitivity of cancer cells to 5-fluorouracil and methotrexate.

Authors:  S-E Kim; P D Cole; R C Cho; A Ly; L Ishiguro; K-J Sohn; R Croxford; B A Kamen; Y-I Kim
Journal:  Br J Cancer       Date:  2013-09-17       Impact factor: 7.640

9.  FPGS rs1544105 polymorphism is associated with treatment outcome in pediatric B-cell precursor acute lymphoblastic leukemia.

Authors:  Shu-Guang Liu; Chao Gao; Rui-Dong Zhang; Ying Jiao; Lei Cui; Wei-Jing Li; Zhen-Ping Chen; Min-Yuan Wu; Hu-Yong Zheng; Xiao-Xi Zhao; Zhi-Xia Yue; Zhi-Gang Li
Journal:  Cancer Cell Int       Date:  2013-10-29       Impact factor: 5.722

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.